Corpus Intelligence IC Memo — ADVENTHEALTH CENTRAL TEXAS 2026-04-26 17:22 UTC
IC Memo — ADVENTHEALTH CENTRAL TEXAS
Investment Committee Memorandum | TX | 208 beds | Grade C | EBITDA uplift $10.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ADVENTHEALTH CENTRAL TEXAS

CCN 450152 | BELL, TX | 208 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ADVENTHEALTH CENTRAL TEXAS is a 208-bed under-performing / distressed in BELL, TX with $139.3M in net patient revenue and a -6.5% operating margin. The hospital serves a payer mix of 20.2% Medicare, 10.4% Medicaid, and 69.4% commercial.

Thesis: Undervalued. Our ML models identify $10.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.5% to 0.9% (+736bps).

Net Revenue HCRIS$139.3M
Current EBITDA COMPUTED$-9.0M
Operating Margin COMPUTED-6.5%
Occupancy HCRIS37.2%
Revenue / Bed COMPUTED$670K
Net-to-Gross HCRIS20.9%
Distress Probability ML52.5%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
148
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -6.5% places it below the state median. Among 148 size-comparable peers (104-416 beds), the median margin is 4.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (104-416), prioritizing same-state peers. 148 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ADVENTHEALTH CENTRAL TEXAS (Target)TX208$139.3M-6.5%
CHILDRENS MEDICAL CENTER OF DATX377$1.56B10.3%
DELL CHILDRENS MEDICAL CENTERTX262$901.9M25.5%
DOCTORS HOSPITAL AT RENAISSANCTX394$847.8M9.2%
ASCENSION SETON MEDICAL CENTERTX391$702.5M12.6%
DRISCOLL CHILDRENS HOSPITALTX215$694.3M29.4%
ROUND ROCK HOSPITALTX165$681.4M8.7%
METHODIST SUGAR LAND HOSPITALTX337$679.6M12.6%
METHODIST WILLOWBROOK HOSPITALTX346$661.8M10.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $10.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.9M+210bp18mo
Cost to Collect4.5%2.5%$2.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.7M+122bp9mo
Clean Claim Rate88.0%96.0%$89K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.9M
Cost to Collect
$2.8M
Denial Rate Reduction
$2.8M
A/R Days Reduction
$1.7M
Clean Claim Rate
$89K
Total EBITDA Uplift$10.3M
Current EBITDA$-9.0M
+ RCM Uplift+$10.3M
Pro Forma EBITDA$1.2M
Current Margin-6.5%
Pro Forma Margin0.9%
WC Released (1x)$5.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-13.9M$43.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-13.9M$42.8M0.00x-100.0%
Bull Case9.0x11.0x$-12.5M$72.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-12.5M$75.0M0.00x-100.0%
Bear Case11.0x10.0x$-15.3M$-3.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-15.3M$-9.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 52.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 148 hospitals with 104-416 beds
  • Same-state prioritization (n=149)
  • Comp margins: P25=-7.1% / P50=4.9% / P75=13.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.